Theodora Katsila and Alexandros P. Siskos contributed equally to this work.
Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry†
Article first published online: 22 JUN 2011
Copyright © 2011 Wiley Periodicals, Inc.
Mass Spectrometry Reviews
Volume 31, Issue 1, pages 110–133, January/February 2012
How to Cite
Katsila, T., Siskos, A. P. and Tamvakopoulos, C. (2012), Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry. Mass Spectrom. Rev., 31: 110–133. doi: 10.1002/mas.20340
- Issue published online: 16 DEC 2011
- Article first published online: 22 JUN 2011
- peptide/protein drug;
- mass spectrometry;
- structure elucidation;
Peptide and protein drugs have evolved in recent years into mainstream therapeutics, representing a significant portion of the pharmaceutical market. Peptides and proteins exhibit highly diverse structures, broad biological activities as hormones, neurotransmitters, structural proteins, metabolic modulators and therefore have a significant role as both therapeutics and biomarkers. Understanding the metabolism of synthetic or biotechnologically derived peptide and protein drugs is critical for pharmaceutical development as metabolism has a significant impact on drug efficacy and safety. Although the same principles of pharmacokinetics and metabolism of small molecule drugs apply to peptide and protein drugs, there are few notable differences. Moreover, the study of peptide and protein drug metabolism is a rather complicated process which requires sophisticated analytical techniques, and mass spectrometry based approaches have provided the capabilities for efficient and reliable quantification, characterization, and metabolite identification. This review article will focus on the current use of mass spectrometry for the study of the metabolism of peptide and protein drugs. © 2011 Wiley Periodicals, Inc., Mass Spec Rev 31:110–133, 2012